Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.59 USD
-0.18 (-4.77%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $3.58 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Sutro Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -106.79 | -119.20 | -105.54 | -32.13 | -55.74 |
Depreciation/Amortization & Depletion | -2.26 | 5.33 | 7.63 | 4.79 | 3.32 |
Net Change from Assets/Liabilities | -34.38 | 104.41 | -17.62 | -11.49 | -23.26 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 31.81 | 13.02 | 33.85 | -28.98 | 10.67 |
Net Cash From Operating Activities | -111.62 | 3.55 | -81.68 | -67.80 | -65.02 |
Property & Equipment | -4.32 | 20.88 | -15.32 | -7.13 | -3.48 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.39 | -55.91 | -82.00 | 7.64 | -47.65 |
Other Investing Activities | 0.00 | 0.01 | 0.01 | 0.09 | 0.00 |
Net Cash from Investing Activities | -3.92 | -35.02 | -97.32 | 0.60 | -51.13 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 12.29 | 0.27 | 2.49 | 1.86 | 0.18 |
Issuance (Repayment) of Debt | -12.50 | -9.38 | 0.00 | 15.00 | -5.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 137.77 | 57.42 | 0.78 | 252.39 | 0.64 |
Net Cash from Financing Activities | 137.55 | 48.31 | 3.26 | 269.25 | -4.18 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 22.01 | 16.84 | -175.74 | 202.05 | -120.34 |
Cash at Beginning of Period | 48.13 | 31.29 | 207.02 | 4.98 | 125.31 |
Cash at End of Period | 70.14 | 48.13 | 31.29 | 207.02 | 4.98 |
Diluted Net EPS | -1.78 | -2.35 | -2.29 | -0.99 | -2.43 |
Fiscal Year End for Sutro Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -106.23 | -58.21 | -106.79 | -137.86 | -88.57 |
Depreciation/Amortization & Depletion | -1.93 | -0.89 | -2.26 | -0.94 | -0.28 |
Net Change from Assets/Liabilities | 31.76 | -16.62 | -34.38 | -12.79 | -16.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.12 | 10.98 | 31.81 | 25.90 | 13.21 |
Net Cash From Operating Activities | -55.29 | -64.74 | -111.62 | -125.69 | -92.19 |
Property & Equipment | -1.20 | -0.45 | -4.32 | -2.87 | -2.55 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -15.07 | 64.55 | 0.39 | 22.46 | 136.15 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -16.27 | 64.11 | -3.92 | 19.59 | 133.61 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 96.64 | 0.12 | 12.29 | 12.29 | 12.29 |
Issuance (Repayment) of Debt | -4.08 | -4.08 | -12.50 | -9.38 | -6.25 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.50 | 0.54 | 137.77 | 137.77 | 140.38 |
Net Cash from Financing Activities | 93.06 | -3.43 | 137.55 | 140.68 | 146.42 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 21.51 | -4.07 | 22.01 | 34.58 | 187.84 |
Cash at Beginning of Period | 70.14 | 70.14 | 48.13 | 48.13 | 48.13 |
Cash at End of Period | 91.65 | 66.08 | 70.14 | 82.71 | 235.97 |
Diluted Net EPS | -0.59 | -0.95 | 0.52 | -0.81 | -0.64 |